Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Urothelial Cancer × vinflunine × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 5 Breast Neoplasms 3 Urothelial Cancer 1 Ureteral Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasm Metastasis 1 Locally Advanced or Metastatic Unresectable Urothelial Cancer 1 Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 3 Cisplatin 3 Carboplatin 3 pembrolizumab 2 vinflunine 1 tremelimumab 1 erdafitinib 1 enfortumab vedotin 1 durvalumab 1 Nivolumab 1 Ipilimumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03390504 2026-02-02

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡